Clinica Review of 2007: Drug-eluting stents recover from the last year's bad press
This article was originally published in Clinica
A year ago, the cardiology world was reeling from study results suggesting that drug-eluting stents were more dangerous than their bare-metal equivalents. 2007 saw the devices almost fully vindicated, writes Elizabeth Cairns
You may also be interested in...
Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism.
The Belgian biotech has divested its drug discovery services unit in Croatia which was making a nice profit but was not a priority as Galapagos concentrates on setting up its commercial operations in Europe.
In the first of a two-part article on transparency provisions for the new EU clinical trial portal, the Pink Sheet reports on aspects that sponsors must consider to protect commercially confidential information in their clinical trial applications. The second article will look at the approach taken by Merck and discuss outstanding hot topics in relation to transparency and CTIS.